These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 25435145)
1. 2-Substituted Nγ-glutamylanilides as novel probes of ASCT2 with improved potency. Schulte ML; Dawson ES; Saleh SA; Cuthbertson ML; Manning HC Bioorg Med Chem Lett; 2015 Jan; 25(1):113-6. PubMed ID: 25435145 [TBL] [Abstract][Full Text] [Related]
2. 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport. Schulte ML; Khodadadi AB; Cuthbertson ML; Smith JA; Manning HC Bioorg Med Chem Lett; 2016 Feb; 26(3):1044-1047. PubMed ID: 26750251 [TBL] [Abstract][Full Text] [Related]
3. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds. Ndaru E; Garibsingh RA; Shi Y; Wallace E; Zakrepine P; Wang J; Schlessinger A; Grewer C J Gen Physiol; 2019 Mar; 151(3):357-368. PubMed ID: 30718375 [TBL] [Abstract][Full Text] [Related]
4. Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Esslinger CS; Cybulski KA; Rhoderick JF Bioorg Med Chem; 2005 Feb; 13(4):1111-8. PubMed ID: 15670919 [TBL] [Abstract][Full Text] [Related]
5. Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy. Jiang H; Zhang N; Tang T; Feng F; Sun H; Qu W Pharmacol Res; 2020 Aug; 158():104844. PubMed ID: 32438035 [TBL] [Abstract][Full Text] [Related]
6. Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening. Colas C; Grewer C; Otte NJ; Gameiro A; Albers T; Singh K; Shere H; Bonomi M; Holst J; Schlessinger A PLoS Comput Biol; 2015 Oct; 11(10):e1004477. PubMed ID: 26444490 [TBL] [Abstract][Full Text] [Related]
7. Cysteine is not a substrate but a specific modulator of human ASCT2 (SLC1A5) transporter. Scalise M; Pochini L; Pingitore P; Hedfalk K; Indiveri C FEBS Lett; 2015 Nov; 589(23):3617-23. PubMed ID: 26492990 [TBL] [Abstract][Full Text] [Related]
8. Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2. Singh K; Tanui R; Gameiro A; Eisenberg G; Colas C; Schlessinger A; Grewer C Bioorg Med Chem Lett; 2017 Feb; 27(3):398-402. PubMed ID: 28057420 [TBL] [Abstract][Full Text] [Related]
9. Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation. Yu X; Plotnikova O; Bonin PD; Subashi TA; McLellan TJ; Dumlao D; Che Y; Dong YY; Carpenter EP; West GM; Qiu X; Culp JS; Han S Elife; 2019 Oct; 8():. PubMed ID: 31580259 [TBL] [Abstract][Full Text] [Related]
10. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325 [TBL] [Abstract][Full Text] [Related]
11. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838 [TBL] [Abstract][Full Text] [Related]
12. Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity. Oppedisano F; Catto M; Koutentis PA; Nicolotti O; Pochini L; Koyioni M; Introcaso A; Michaelidou SS; Carotti A; Indiveri C Toxicol Appl Pharmacol; 2012 Nov; 265(1):93-102. PubMed ID: 23010140 [TBL] [Abstract][Full Text] [Related]
13. Interaction of the neutral amino acid transporter ASCT2 with basic amino acids. Ndaru E; Garibsingh RA; Zielewicz L; Schlessinger A; Grewer C Biochem J; 2020 Apr; 477(8):1443-1457. PubMed ID: 32242892 [TBL] [Abstract][Full Text] [Related]
14. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells. Wang W; Pan H; Ren F; Chen H; Ren P Biosci Rep; 2022 Mar; 42(3):. PubMed ID: 35237783 [TBL] [Abstract][Full Text] [Related]
15. Establishment of monoclonal antibodies against cell surface domains of ASCT2/SLC1A5 and their inhibition of glutamine-dependent tumor cell growth. Suzuki M; Toki H; Furuya A; Ando H Biochem Biophys Res Commun; 2017 Jan; 482(4):651-657. PubMed ID: 27865832 [TBL] [Abstract][Full Text] [Related]
16. Cys Site-Directed Mutagenesis of the Human SLC1A5 (ASCT2) Transporter: Structure/Function Relationships and Crucial Role of Cys467 for Redox Sensing and Glutamine Transport. Scalise M; Pochini L; Console L; Pappacoda G; Pingitore P; Hedfalk K; Indiveri C Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495336 [TBL] [Abstract][Full Text] [Related]
17. ASCT2: a potential cancer drug target. Wahi K; Holst J Expert Opin Ther Targets; 2019 Jul; 23(7):555-558. PubMed ID: 31159623 [No Abstract] [Full Text] [Related]
18. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth. Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480 [TBL] [Abstract][Full Text] [Related]
19. Rational design of ASCT2 inhibitors using an integrated experimental-computational approach. Garibsingh RA; Ndaru E; Garaeva AA; Shi Y; Zielewicz L; Zakrepine P; Bonomi M; Slotboom DJ; Paulino C; Grewer C; Schlessinger A Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507995 [TBL] [Abstract][Full Text] [Related]
20. The role of ASCT2 in cancer: A review. Liu Y; Zhao T; Li Z; Wang L; Yuan S; Sun L Eur J Pharmacol; 2018 Oct; 837():81-87. PubMed ID: 30025811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]